Search - tctmd.com

Displaying 321 - 340 of 413

Sort: Relevancy | Date

Presentation

Potential Lifetime Cost-effectiveness ofCatheter-Based Renal Sympathetic Denervation in Patients with Resistant Hypertension

Presenter: Marc Dorenkamp

November 29, 2012

News Daily News

Transfemoral—But Not Transapical—TAVR More Cost-Effective Than Surgery

Caitlin E. Cox

November 12, 2012

News Daily News

La TAVR Transfemoral, no la Transapical es Más Rentable que la Cirugía

Caitlin E. Cox

November 12, 2012

News Conference News AHA 2012

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Jason Kahn

November 11, 2012

Presentation

Cost-Effectiveness of TAVR vs. Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis

Presenter: M.R. Reynolds

November 08, 2012

News Conference News AHA 2012

ASCERT: CABG More Cost-Effective Than PCI Over Long Term

Jason Kahn

November 05, 2012

News Conference News AHA 2012

Pair of Studies Look at Cost Effectiveness of PCI in Different Populations

Jason Kahn

November 04, 2012

Presentation TCT 2012

DCB Cost-Effectiveness Analysis: What Results Must Be Seen for Success in the United States?

Presenter: Duane Pinto

October 25, 2012

News Conference News TCT 2012

Extended EVEREST II Data Examine Safety, Efficacy of MitraClip as Well as Cost Effectiveness

October 25, 2012

Presentation TCT 2012

FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease

Presenter: William Fearon

October 24, 2012

News Industry News

FFR-Guided PCI Demonstrates Cost-Effectiveness When Compared to Medical Therapy for Stable Coronary Artery Disease

October 24, 2012

News Conference News TCT 2012

FAME 2: FFR-Guided PCI Cost Effective vs. Medical Therapy

October 24, 2012

News Industry News

Data from FAME II Trial Concludes FFR-Guided PCI is Cost Effective and Improves Patient Outcomes

October 24, 2012

Presentation TCT 2012

TCT-82. Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared with 5 Alternative Anticoagulation Strategies for Stroke Prevention in Atrial...

Presenter: Bryan Yan

October 23, 2012

Presentation TCT 2012

Quality-of-Life and Cost-Effectiveness After LAA Closure

Presenter: Vivek Reddy

October 23, 2012

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

Presentation TCT 2012

Early Insights on Cost-effectiveness After TAVR

Presenter: Matthew Reynolds

October 22, 2012

News Conference News TCT 2012

PARTNER Analyses Provide Important Insights into TAVR

October 22, 2012

Presentation TCT 2012

An Introduction to Cost-Effectiveness Analyses: Who Pays (and Should They)?

Presenter: David Cohen

October 22, 2012

News Daily News

Apixaban Surpasses Warfarin At All Risk Levels in A-Fib Patients

Caitlin E. Cox

October 04, 2012

Advertisement

Potential Lifetime Cost-effectiveness ofCatheter-Based Renal Sympathetic Denervation in Patients with Resistant Hypertension

Transfemoral—But Not Transapical—TAVR More Cost-Effective Than Surgery

La TAVR Transfemoral, no la Transapical es Más Rentable que la Cirugía

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Cost-Effectiveness of TAVR vs. Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis

ASCERT: CABG More Cost-Effective Than PCI Over Long Term

Pair of Studies Look at Cost Effectiveness of PCI in Different Populations

DCB Cost-Effectiveness Analysis: What Results Must Be Seen for Success in the United States?

Extended EVEREST II Data Examine Safety, Efficacy of MitraClip as Well as Cost Effectiveness

FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease

FFR-Guided PCI Demonstrates Cost-Effectiveness When Compared to Medical Therapy for Stable Coronary Artery Disease

FAME 2: FFR-Guided PCI Cost Effective vs. Medical Therapy

Data from FAME II Trial Concludes FFR-Guided PCI is Cost Effective and Improves Patient Outcomes

TCT-82. Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared with 5 Alternative Anticoagulation Strategies for Stroke Prevention in Atrial...

Quality-of-Life and Cost-Effectiveness After LAA Closure

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

Early Insights on Cost-effectiveness After TAVR

PARTNER Analyses Provide Important Insights into TAVR

An Introduction to Cost-Effectiveness Analyses: Who Pays (and Should They)?

Apixaban Surpasses Warfarin At All Risk Levels in A-Fib Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content